Tango Therapeutics, Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Tango Therapeutics, Inc. (TNGX) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 23.70 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-11
- Tango Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 25.98M shares, a 2.50% increase year-over-year.
- Tango Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 25.35M shares, a 16.04% increase year-over-year.
- Tango Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 21.84M shares, a 23.75% increase year-over-year.
- Tango Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-03-31 was 17.65M shares, a 38.53% increase year-over-year.
- Tango Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 21.73M shares, a 4.34% increase from fiscal 2024.
- Tango Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 20.82M shares, a 19.05% increase from fiscal 2023.
- Tango Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 17.49M shares, a 35.35% increase from fiscal 2022.
- Tango Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 12.92M shares, a 37.89% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|
| 2026-06-30 | 23.70M shares 10-Q · filed 2026-08-11 | |||
| 2026-03-31 | 25.98M shares 10-Q · filed 2026-05-13 | |||
| 2025-12-31 | 21.73M shares 10-K · filed 2026-03-05 | |||
| 2025-09-30 | 23.86M shares 10-Q · filed 2025-11-04 | |||
| 2025-06-30 | 25.14M shares 10-Q · filed 2026-08-11 | |||
| 2025-03-31 | 25.35M shares 10-Q · filed 2026-05-13 | |||
| 2024-12-31 | 20.82M shares 10-K · filed 2026-03-05 | |||
| 2024-09-30 | 21.02M shares 10-Q · filed 2025-11-04 | |||
| 2024-06-30 | 21.75M shares 10-Q · filed 2025-08-05 | |||
| 2024-03-31 | 21.84M shares 10-Q · filed 2024-05-08 | |||
| 2023-12-31 | 17.49M shares 10-K · filed 2026-03-05 | |||
| 2023-09-30 | 17.85M shares 10-Q · filed 2024-11-06 | |||
| 2023-06-30 | 17.68M shares 10-Q · filed 2024-08-07 | |||
| 2023-03-31 | 17.65M shares 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | 12.92M shares 10-K · filed 2025-02-27 | |||
| 2022-09-30 | 12.70M shares 10-Q · filed 2023-11-08 | |||
| 2022-06-30 | 12.43M shares 10-Q · filed 2023-08-07 | |||
| 2022-03-31 | 12.74M shares 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | 9.37M shares 10-K · filed 2023-03-27 | |||
| 2021-09-30 | 8.83M shares 10-Q · filed 2022-11-10 | |||
| 2021-06-30 | 6.50M shares 10-Q · filed 2022-08-10 | |||
| 2021-03-31 | 6.53M shares 10-Q · filed 2022-05-11 | |||
| 2020-12-31 | 4.35M shares 10-K · filed 2022-03-28 | |||
| 2020-09-30 | 3.98M shares 10-Q · filed 2021-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |